Pen-injector: Alina pen-injector for diabetes and weight management - Stevanato Group
Alina is a user-friendly disposable pen-injector platform for diabetes care, based on proven technology. Alina® pen-injector for diabetes and weight management
Home - Managing Complexity, Delivering Value - Stevanato Group > Products & Capabilities - Stevanato Group > Drug Delivery systems and solutions - Stevanato Group > Proprietary and licensed devices - Stevanato Group > Pen-injector: Alina pen-injector for diabetes and weight management - Stevanato Group
page-wrapper

Easy to use disposable pen injector platform for variable and multi-dose treatments, based on proven technology

Alina® is a variable-dose pen injector developed by Stevanato Group based on Axis-D intellectual property and technology exclusively licensed from pen injector device expert Haselmeier, for the treatment of diabetes, obesity, and other therapeutic areas.

The pen injector is manufactured at Stevanato Group’s FDA-inspected facility in Germany. Access to tooling and sub-assembly equipment is available to clients who are looking to balance investments for their device programs and minimize time-to-market. Dedicated production tooling and lines are available if requested due to customization considerations or to support overall risk mitigation strategies.

A range of final assembly equipment for this pen injector from our operations in Denmark and Italy can be made available to clients upon request or we can work with your existing equipment partner. Support from our glass primary container experts to final assembly and packing solutions is offered.

Alina® features an appealing and functional design, including an easy-to-dial mechanism, optimized injection force for patient comfort, and a readable display. This platform pen injector offers a range of customization from dosing and color selection to a more customized industrial design based on the needs of the pharmaceutical client.

SG Alina - Pen Injector
SG Alina- Pen Injector

The trademark Alina is a registered right exclusively owned by Stevanato Group or its affiliates.

Therapeutic Areas
235 Diabetes

Diabetes care

(Insulin and GLP-1)

406 Excessweight

Weight Management

199 Chemical Molecule

Other therapeutic areas
(e.g. cardiovascular disease, gastrointestinal disorders, pain management, neurological disorders, arthritis)

Standard pen specifications at a glance

317 Dose Indication
Clear pre-injection dose indication to avoid underdosing
326 Pen needle
Device compatible with standard pen needles
328_dose error correction
Dose error correction possible with simple dial back
214A_Feedback 2
Visual and audible feedbacks for dose setting, correction and injection

Manufacturing pen features

89 Filled Cartridge
Suitable for ISO 3mL glass cartridges, and optimized for Stevanato Group’s Nexa® cartridges
325 User contact alina
A range of supportive studies are available
13 Quality
Design for manufacturing and ease of final assembly have been considered
331_Pen injector volume scale
Standard volume scale on cartridge holder available
329A_Alina custom 2.eps
Additional customization can be offered
267A_SVMArm_Pen Alina
Precise piston positioning during end-assembly
25 Regulatory Expertise
Testing and verification according to ISO 11608-1:2022

Integrated capabilities

89_Cartridge filled circle
3mL glass cartridge available in EZ-fill® or bulk
66_analytical circle
Characterization of primary container closure system
196A_Molding circle
Precision manufacturing including molding, tooling and assembly of components
267A_SVMarm alina circle
Sub-assembly and final assembly equipment available
275_project mangm circle
Technology and intellectual property licensed from partner Haselmeier with additional support from our internal R&D team

Press Releases

Press Release 2022

Stevanato Group extends pen injector technology licensing agreement with Haselmeier

Press Release 2021

Stevanato Group to showcase the benefits of an integrated solutions approach at CPhI Worldwide Conference, November 9-11

Article

A flexible platform device to streamline market launches
"Tailoring GLP-1 Biosimilar
Delivery Systems for
the Growing Obesity Market"
Join our Webinar!
Dec. 4, 4:00pm CET
"Tailoring GLP-1 Biosimilar
Delivery Systems for
the Growing Obesity Market"
Join our Webinar!
Dec. 4, 4:00pm CET
Interested in Alina?
Submit your request